ACM
REGN icon

Advent Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Advent Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Hold
0
– – – 489
2013
Q3 		– Sell
-2,000
Closed -$450K – 599
2013
Q2 		$450K Buy
+2,000
New +$466K 0.01% 486

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Advent Capital Management's REGN Position: Q4 2013 in Review

Advent Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2013 at 0 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #489.

Advent Capital Management first reported a position in REGN in Q2 2013 and has held it in 1 quarter since. The position peaked at $450K in Q2 2013. 438 funds tracked by Wall St. Rank hold REGN as of Q4 2013.

  • Advent Capital Management held 0 shares of Regeneron Pharmaceuticals worth $1.1M as of Q4 2013.
  • Advent Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q4 2013.
  • Regeneron Pharmaceuticals made up 0.01% of Advent Capital Management's portfolio in Q4 2013, its #489 holding.
  • Advent Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 1 quarter since.
  • Advent Capital Management's Regeneron Pharmaceuticals position peaked at $450K in Q2 2013.
  • 438 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2013.

Based on Advent Capital Management's 13F filing for Q4 2013, filed 11 Feb 2014.